<!doctype html><html lang=en><head><meta charset=utf-8><meta name=description content="Anti-platelet  Aspirin - prevents production of thromboxane A2 inhibiting platelet aggregation. Used in low doses (75mg/day PO) for secondary prevention following [[myocardial infarction]], [[Transient Ischemic Attack]] and [[Stroke]]."><meta property="og:title" content="Cardiovascular drugs"><meta property="og:description" content="Anti-platelet  Aspirin - prevents production of thromboxane A2 inhibiting platelet aggregation. Used in low doses (75mg/day PO) for secondary prevention following [[myocardial infarction]], [[Transient Ischemic Attack]] and [[Stroke]]."><meta property="og:type" content="website"><meta property="og:image" content="https://notes.nosos.co.uk/icon.png"><meta property="og:url" content="https://notes.nosos.co.uk/Cardiovascular-drugs/"><meta property="og:width" content="200"><meta property="og:height" content="200"><meta name=twitter:card content="summary"><meta name=twitter:title content="Cardiovascular drugs"><meta name=twitter:description content="Anti-platelet  Aspirin - prevents production of thromboxane A2 inhibiting platelet aggregation. Used in low doses (75mg/day PO) for secondary prevention following [[myocardial infarction]], [[Transient Ischemic Attack]] and [[Stroke]]."><meta name=twitter:image content="https://notes.nosos.co.uk/icon.png"><title>Cardiovascular drugs</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://notes.nosos.co.uk//icon.png media="(prefers-color-scheme: dark"><link rel="shortcut icon" type=image/png href=https://notes.nosos.co.uk//icon.png-dark.png media="(prefers-color-scheme: light"><link href=https://notes.nosos.co.uk/styles.61b7f083b0774b0c42e780c0bc55ee73.min.css rel=stylesheet><link href=https://notes.nosos.co.uk/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://notes.nosos.co.uk/js/darkmode.660ec90bf737ee058bec1d99e0222946.min.js></script>
<script src=https://notes.nosos.co.uk/js/util.00639692264b21bc3ee219733d38a8be.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/npm/@floating-ui/core@1.2.1></script>
<script src=https://cdn.jsdelivr.net/npm/@floating-ui/dom@1.2.1></script>
<script defer src=https://notes.nosos.co.uk/js/popover.aa9bc99c7c38d3ae9538f218f1416adb.min.js></script>
<script defer src=https://notes.nosos.co.uk/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://notes.nosos.co.uk/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://notes.nosos.co.uk/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://notes.nosos.co.uk/",fetchData=Promise.all([fetch("https://notes.nosos.co.uk/indices/linkIndex.50f0bdeb7c333b5a7c5a55fc231c1ace.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://notes.nosos.co.uk/indices/contentIndex.a0abd732c73fb2da73077549218715d4.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://notes.nosos.co.uk",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!0;drawGraph("https://notes.nosos.co.uk",t,[{"/moc":"#4388cc"}],t?{centerForce:.3,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.2,linkDistance:30,opacityScale:1,repelForce:.5,scale:.9}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}var i=document.getElementsByClassName("mermaid");i.length>0&&import("https://unpkg.com/mermaid@9/dist/mermaid.esm.min.mjs").then(e=>{e.default.init()});function a(n){const e=n.target,t=e.className.split(" "),s=t.includes("broken"),o=t.includes("internal-link");plausible("Link Click",{props:{href:e.href,broken:s,internal:o,graph:!1}})}const r=document.querySelectorAll("a");for(link of r)link.className.includes("root-title")&&link.addEventListener("click",a,{once:!0})},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'â€™':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/notes.nosos.co.uk\/js\/router.d6fe6bd821db9ea97f9aeefae814d8e7.min.js"
    attachSPARouting(init, render)
  </script><script defer data-domain=notes.nosos.co.uk src=https://plausible.io/js/script.js></script>
<script>window.plausible=window.plausible||function(){(window.plausible.q=window.plausible.q||[]).push(arguments)}</script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=Search placeholder="Search for something..."><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://notes.nosos.co.uk/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a class=root-title href=https://notes.nosos.co.uk/>Home</a></h1><div class=spacer></div><div id=search-icon><p>Search</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">Search Icon</title><desc id="desc">Icon to open search</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>Light Mode</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>Dark Mode</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Cardiovascular drugs</h1><p class=meta>Last updated
Jan 18, 2024
<a href=https://github.com/shaggy2922/quartz/tree/hugo/content/Cardiovascular%20drugs.md rel=noopener>Edit Source</a></p><ul class=tags><li><a href=https://notes.nosos.co.uk/tags/Cardiovascular/>Cardiovascular</a></li></ul><aside class=mainTOC><details><summary>Table of Contents</summary><nav id=TableOfContents><ol><li><a href=#anti-platelet>Anti-platelet</a></li><li><a href=#anticoagulants>Anticoagulants</a></li><li><a href=#beta-blockers>$\beta$ blockers</a></li><li><a href=#acei>ACEi</a></li><li><a href=#diuretics>Diuretics</a></li><li><a href=#vasodilators>Vasodilators</a></li><li><a href=#calcium-antagonists>Calcium antagonists</a></li><li><a href=#digoxin>Digoxin</a></li><li><a href=#sodium-channel-blockers>Sodium channel blockers</a></li><li><a href=#amiodarone>Amiodarone</a></li><li><a href=#ivabradine>Ivabradine</a></li><li><a href=#statins>Statins</a></li></ol></nav></details></aside><a href=#anti-platelet><h2 id=anti-platelet><span class=hanchor arialabel=Anchor># </span>Anti-platelet</h2></a><ul><li><strong><em>Aspirin</em></strong> - prevents production of thromboxane A2 inhibiting platelet aggregation. Used in low doses (75mg/day PO) for secondary prevention following <a href=/myocardial-infarction rel=noopener class=internal-link data-src=/myocardial-infarction>myocardial infarction</a>, <a href=/Transient-Ischemic-Attack rel=noopener class=internal-link data-src=/Transient-Ischemic-Attack>Transient Ischemic Attack</a> and <a href=/Stroke rel=noopener class=internal-link data-src=/Stroke>Stroke</a>. Also used for patients with <a href=/Angina rel=noopener class=internal-link data-src=/Angina>Angina</a> or <a href=/peripheral-vascular-disease rel=noopener class=internal-link data-src=/peripheral-vascular-disease>peripheral vascular disease</a>. Also an NSAID and may worsen GI symptoms.</li><li><em><strong>P2Y12 antagonists</strong></em> - (clopidogrel, pasugrel, ticagrelor) also block platelet aggregation but cause less gastric irritation. Used with aspirin after PCI, and in <a href=/Acute-Coronary-Syndrome rel=noopener class=internal-link data-src=/Acute-Coronary-Syndrome>Acute Coronary Syndrome</a></li></ul><a href=#anticoagulants><h2 id=anticoagulants><span class=hanchor arialabel=Anchor># </span>Anticoagulants</h2></a><ul><li><em><strong>DOACs</strong></em> - Xa inhibitors (apixaban), direct thrombin inhibitors (dabigatran) for treatment of <a href=/Atrial-Fibrillation rel=noopener class=internal-link data-src=/Atrial-Fibrillation>Atrial Fibrillation</a> and clots.</li><li>Warfarin is still used for people with mechanical heart valves</li><li>Anticoagulants used in <a href=/Acute-Coronary-Syndrome rel=noopener class=internal-link data-src=/Acute-Coronary-Syndrome>Acute Coronary Syndrome</a> include LMWH, fondaparinux (Xa inhibitor) & bivalirudin (thrombin inhibitor)</li></ul><a href=#beta-blockers><h2 id=beta-blockers><span class=hanchor arialabel=Anchor># </span>$\beta$ blockers</h2></a><ul><li>Antagonise the sympathetic nervous system</li><li>Blocking $\beta_1$ is negatively inotropic and chronotropic</li><li>Blocking $\beta_2$ induces peripheral vasoconstriction and bronchoconstriction</li><li>Propanolol is non selective, bisoprolol is $\beta_1$ selective</li><li>Used in <a href=/Angina rel=noopener class=internal-link data-src=/Angina>Angina</a>, <a href=/Essential-hypertension rel=noopener class=internal-link data-src=/Essential-hypertension>hypertension</a>, post <a href=/myocardial-infarction rel=noopener class=internal-link data-src=/myocardial-infarction>myocardial infarction</a>, <a href=/Heart-Failure rel=noopener class=internal-link data-src=/Heart-Failure>Heart Failure</a></li><li>Contraindicated in <em>severe</em> <a href=/asthma rel=noopener class=internal-link data-src=/asthma>asthma</a>/<a href=/COPD rel=noopener class=internal-link data-src=/COPD>COPD</a>, <a href=/Heart-Block rel=noopener class=internal-link data-src=/Heart-Block>Heart Block</a></li></ul><a href=#acei><h2 id=acei><span class=hanchor arialabel=Anchor># </span>ACEi</h2></a><ul><li>Causes vasodilation and excretion of sodium and water. eg Ramipril</li><li>Used in <a href=/Essential-hypertension rel=noopener class=internal-link data-src=/Essential-hypertension>hypertension</a>, <a href=/Heart-Failure rel=noopener class=internal-link data-src=/Heart-Failure>Heart Failure</a>, post <a href=/myocardial-infarction rel=noopener class=internal-link data-src=/myocardial-infarction>myocardial infarction</a></li><li>Can cause hyperkalaemia</li><li>Put pressure on the kidneys so hold in <a href=/Acute-Kidney-Injury rel=noopener class=internal-link data-src=/Acute-Kidney-Injury>Acute Kidney Injury</a> and monitor U&Es for kidney function</li><li>Can cause a dry cough so may switch to ARB (ARB contraindicated in pregnancy however)</li></ul><a href=#diuretics><h2 id=diuretics><span class=hanchor arialabel=Anchor># </span>Diuretics</h2></a><ul><li><em><strong>Loop diuretics</strong></em> - eg furosemide inhibit NA/2Cl/K co-transporter. $\downarrow$ Na$^+$ $\downarrow$ K$^+$ $\downarrow$ Ca$^{2+}$. <a href=/Heart-Failure rel=noopener class=internal-link data-src=/Heart-Failure>Heart Failure</a></li><li><strong><em>Thiazide/thiazide-like diuretics</em></strong> are used in <a href=/Essential-hypertension rel=noopener class=internal-link data-src=/Essential-hypertension>hypertension</a> (indapamide) and <a href=/Heart-Failure rel=noopener class=internal-link data-src=/Heart-Failure>Heart Failure</a> (metolazone). $\downarrow$ K$^+$ $\uparrow$ Ca$^{2+}$ $\downarrow$ Mg$^{2+}$, $\uparrow$ urate ($\pm$ gout).</li><li><em><strong>Potassium sparing diruetics</strong></em> - aldosterone antagonists (spironolactone, eplerenone)</li></ul><a href=#vasodilators><h2 id=vasodilators><span class=hanchor arialabel=Anchor># </span>Vasodilators</h2></a><ul><li>Used in <a href=/Heart-Failure rel=noopener class=internal-link data-src=/Heart-Failure>Heart Failure</a>, <a href=/Coronary-Artery-Disease rel=noopener class=internal-link data-src=/Coronary-Artery-Disease>Ischemic Heart Disease</a>,</li><li><em><strong>Nitrates</strong></em> - preferentially dilate veins and large arteries. $\downarrow$ preload (filling pressure)</li><li><em><strong>Hydralazine</strong></em> - primarily dilate resistance vessels $\downarrow$ after-load (BP)</li><li><em><strong>Prazosin</strong></em> - $\alpha$-blocker dilates veins and arteries</li></ul><a href=#calcium-antagonists><h2 id=calcium-antagonists><span class=hanchor arialabel=Anchor># </span>Calcium antagonists</h2></a><ul><li>$\downarrow$ cell entry of Ca$^{2+}$ in smooth muscle, promoting coronary and peripheral vasodilation and reducing myocardial oxygen use. All current drugs block L-type Ca$^{2+}$ channels but different binding properties cause different effects. <a href=/Essential-hypertension rel=noopener class=internal-link data-src=/Essential-hypertension>hypertension</a> and <a href=/Angina rel=noopener class=internal-link data-src=/Angina>Angina</a></li><li><em><strong>Dihydropyridines</strong></em> - eg <em>amlodipine</em> are mainly peripheral vasodilators and cause a reflex tachycardia so used with a $\beta$-blocker</li><li><em><strong>Non-dihydropyridines</strong></em> - eg <em>verapamil and diltiazem</em> slow conduction at the AV and SV node and may be used to treat dysrhythmias in addition.</li></ul><blockquote class=info-callout><p>Don&rsquo;t give non-dihydropyridines with $\beta$-blockers for risk of severe bradycardia</p></blockquote><a href=#digoxin><h2 id=digoxin><span class=hanchor arialabel=Anchor># </span>Digoxin</h2></a><ul><li>Blocks the Na+/K+ pump. Used to rate control in fast <a href=/Atrial-Fibrillation rel=noopener class=internal-link data-src=/Atrial-Fibrillation>AF</a> (aim for less than 100)</li><li>Weak +ve inotrope, half life of 36 hours</li><li>$\uparrow$ Toxicity risk if $\downarrow$ K$^+$ $\downarrow$ Mg$^{2+}$ or $\uparrow$ Ca$^{2+}$</li><li>May caused ST depression in toxicity <a href=/ECG-Lead-Placement-Interpretation#20b905 rel=noopener class=internal-link data-src=/ECG-Lead-Placement-Interpretation>Digoxin effect</a></li></ul><a href=#sodium-channel-blockers><h2 id=sodium-channel-blockers><span class=hanchor arialabel=Anchor># </span>Sodium channel blockers</h2></a><ul><li>Class I anti-arrhythmics</li><li><em><strong>Procainamide (1a) and Lidocaine (1b)</strong></em> can be used to terminate VT</li><li><em><strong>Flecainide (1c)</strong></em> is useful for <a href=/Atrial-Fibrillation rel=noopener class=internal-link data-src=/Atrial-Fibrillation>Atrial Fibrillation</a> cardioversion and for anti-arrhythmia prophylaxis</li><li>Contraindicated in <a href=/Heart-Failure rel=noopener class=internal-link data-src=/Heart-Failure>Heart Failure</a>, <a href=/Coronary-Artery-Disease rel=noopener class=internal-link data-src=/Coronary-Artery-Disease>Ischemic Heart Disease</a>, <a href=/Heart-Block rel=noopener class=internal-link data-src=/Heart-Block>Heart Block</a>, and valve disease</li></ul><a href=#amiodarone><h2 id=amiodarone><span class=hanchor arialabel=Anchor># </span>Amiodarone</h2></a><ul><li>Class III anti-arrhythmic</li><li>Prolongs cardiac action potential reducing the chance for tacharrythmias</li><li>Used in SVT and VT</li><li>Broad side effects - thyroid disease, liver disease, <a href=/Pulmonary-Fibrosis rel=noopener class=internal-link data-src=/Pulmonary-Fibrosis>Pulmonary Fibrosis</a> and peripheral neuropathy</li><li>Monitor TFTs and LFTs every 6 months</li></ul><a href=#ivabradine><h2 id=ivabradine><span class=hanchor arialabel=Anchor># </span>Ivabradine</h2></a><ul><li>Blocks the pacemaker funny current (small current to give the heart a push to make a contraction). So slows pulse rate without significantly dropping blood pressure</li><li><a href=/Angina rel=noopener class=internal-link data-src=/Angina>Angina</a>, <a href=/Heart-Failure rel=noopener class=internal-link data-src=/Heart-Failure>Heart Failure</a> and off licence in autonomic tachycardia syndromes</li><li>CI in acute <a href=/myocardial-infarction rel=noopener class=internal-link data-src=/myocardial-infarction>myocardial infarction</a>, long QT, bradycardia.</li><li>Many drug interactions including with calcium antagonists</li></ul><a href=#statins><h2 id=statins><span class=hanchor arialabel=Anchor># </span>Statins</h2></a><ul><li>Inhibit HMG-CoA reductase preventing de novo synthesis of cholesterol in the liver. This increases LDL receptor expression on hepatocytes leading to $\downarrow$ LDL cholesterol.</li><li>More effective if given at night</li><li>Generally v well tolerated</li></ul></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>Backlinks</h3><ul class=backlinks><li><a href=/Angina/ data-ctx="Cardiovascular drugs" data-src=/Angina class=internal-link>Angina</a></li></ul></div><div><script src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>Interactive Graph</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://notes.nosos.co.uk/js/graph.6579af7b10c818dbd2ca038702db0224.js></script></div></div><div id=contact_buttons><footer><p>Evan McNab Â© 2024</p><ul><li><a href=https://notes.nosos.co.uk/>Home</a></li><li><a href=https://www.nosos.co.uk/>Nosos</a></li><li><a href=https://notes.nosos.co.uk/tags/>Tags</a></li></ul></footer></div></div></body></html>